Medivation — Merger or Acquisition (May 2016)
41 slides from Medivation's merger presentation, May 6, 2016
Slide 1: Delivering Value Now and Into The Future
Delivering Value Now and Into The Future David Hung, M.D. Founder, President and CEO Exhibit 99.2
Slide 2: Additional Information: Forward-Looking Statements
Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, our anticipat
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures
Slide 4: Table of Contents
Table of Contents Medivation’s Compelling Value Proposition XTANDI Commercial Success and Runway for Growth in Prostate Cancer and Beyond Innovative Late-Stage Pipeline: Talazoparib and Pidilizumab Sanofi’s Substantially Inadequate and Opportunistically-Timed Proposal Conclusion
Slide 5: Medivation's Compelling Value Proposition
Medivation’s Compelling Value Proposition
Slide 6: Why We Are Here
Why We Are Here Graeme Today (with 3rd grandchild) Graeme in 2010 (given 3 weeks to live, enrolled in XTANDI AFFIRM trial) We seek to meaningfully improve the quality of life of patients and families suffering from serious disease by identifying and rapidly and efficiently developing and delivering
Slide 7: We Will Continue To Deliver Substantial Value and Build Upon Our Leadership in Oncology
We Will Continue To Deliver Substantial Value and Build Upon Our Leadership in Oncology Developed the World’s Leading Prostate Cancer Therapy $2.2 Billion Annualized Run Rate in Worldwide XTANDI Net Sales Wholly-Owned, Late-Stage Assets with Blockbuster Potential XTANDI Development: One of the Faste
Slide 8: History of Robust Financial Performance and Significant Shareholder Returns
Medivation Has a History of Robust Financial Performance and Significant Shareholder Returns Source: FactSet and Company filings as of 05/04/16 2016E Non-GAAP revenue represents midpoint of 2016 guidance of $900mm - $970mm Profitability defined as four consecutive positive Non-GAAP net income quarte
Slide 9: Medivation Has Built a Leading Oncology Franchise
Talazoparib (MDV3800) Other Indications Medivation Has Built a Leading Oncology Franchise Products Phase 1 Phase 2 Phase 3 Marketed XTANDI Prostate Cancer AFFIRM + PREVAIL (Led by Medivation) TERRAIN + STRIVE (STRIVE was Led by Medivation) PROSPER (Led by Medivation) EMBARK (Led by Medivation) ARCHE
Slide 10: Creating Long-Term Value: Potential Approvals Through 2020
Creating Long-Term Value: Potential for Up to 7 Approvals Through 2020 Potential Top-Line Results Potential Approval Potential Trial Initiation/Enrollment XTANDI Talazoparib Pidilizumab 2016 2017 2018 2019 2020 mTNBC Dx+ ARCHES PROSPER EMBARK DLBCL if accelerated Ph 2 data in patients with ER/PgR+ B
Slide 11: XTANDI Commercial Success and Runway for Growth in Prostate Cancer and Beyond
XTANDI Commercial Success and Runway for Growth in Prostate Cancer and Beyond
Slide 12: XTANDI Is Among The Top Selling Oncology Products and Still Growing
XTANDI Is Among The Top Selling Oncology Products and Still Growing Top 10 Oncology Drugs by Worldwide Sales Source: WW Product Sales, EvaluatePharma accessed April 2016 2015A WW Revenues ($mm) 2021E WW Revenues 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10
Slide 13: XTANDI Expected to Become Second Best Selling Drug in Europe in 2022
Europe Sales (€mm) Year of European Launch Product Company Therapy Area 2015 2022E Xarelto Bayer Anticoagulation 1,301 2,718 2008 Oncology 586 2,500 2013 Opdivo Bristol-Myers Squibb Oncology 160 2,358 2015 Revlimid Celgene Oncology 1,115 2,216 2007 Triumeq GlaxoSmithKline HIV 242 2,048 2014 XTANDI I
Slide 14: XTANDI Is Now the Leading Novel Hormonal Therapy in the U.S.
3.5 5.0 6.0 XTANDI Is Now the Leading Novel Hormonal Therapy in the U.S. Novel Hormonal Therapy (NHT) Market defined as XTANDI and Zytiga Source: IMS Weekly NPA Data, 13 full consecutive weeks per quarter TRx is the total number of prescriptions 2011 2012 2013 2014 2015 2016 Launched 16 months later
Slide 15: XTANDI Clinical Data Support Longer Treatment Duration in Earlier Lines
XTANDI Clinical Data Support Longer Treatment Duration in Earlier Lines of Prostate Cancer ARCHES 5 Note: PSA=prostate-specific antigen. N Engl J Med 2012; 367:1187-1197. 2) N Engl J Med 2014; 371:424-433; 3) Heidenreich A, et al. EAU Congress. March 20-24, 2015; Madrid, Spain; 4) Penson D, et al. A
Slide 16: Ongoing Phase 3 Trials Significantly Expand XTANDI's Addressable Market
Ongoing Phase 3 Trials Significantly Expand XTANDI’s Addressable Market 73,000 18,000 30,000 12,000 mCRPC¹ M0 CRPC M0 Hormone Sensitive M1 Hormone Sensitive Additional Patient Opportunity = 60,000 Patients ARCHES Addressable patient population defined as all patients who begin treatment in a new lin
Slide 17: XTANDI Will Be Challenging to Displace in Prostate Cancer
XTANDI Will Be Challenging to Displace in Prostate Cancer Source: EvaluatePharma, accessed May 2016 Worldwide sales ($mm) 2015A 2020E 2015–20E CAGR 22% (4%) 29% 4% (5%) (6%)
Slide 18: XTANDI in Breast Cancer Represents a Significant Commercial Opportunity
XTANDI in Breast Cancer Represents a Significant Commercial Opportunity Triple-Negative (TNBC) (15%)* ER/PgR+ and HER2-normal (50%)* HER2+ and AR+ (15%)* San Antonio Breast Cancer Symposium Dec 8-12, 2015 Poster P3-07-25. * Denotes the % this subtype represents of the total breast cancer population
Slide 19: Additional Solid Tumor Indications Provide Significant Upside
Additional Solid Tumor Indications Provide Significant Upside * Potential addressable patient population defined as all lines of treatable metastatic patients in 2016 Sources: MDVN internal analysis; © 2016 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or
Slide 20: XTANDI Has Multiple Near Term Value Creating Events
1H 2016 2H 2016 XTANDI Has Multiple Near Term Value Creating Events… CHMP¹ Positive Opinion Phase 4 PLATO trial Phase 3 TNBC trial Initiate ER/PgR+ breast cancer trial Top-line data TERRAIN and STRIVE publications Expansion / bifurcation of sales force PDUFA for TERRAIN / STRIVE Potential approval P
Slide 21: And Significant Longer-Term Growth Potential
… And Significant Longer-Term Growth Potential Timeline based on current management estimates. 2019 2020 2021 Non-metastatic CRPC – Progressed on ADT mTNBC Dx+ 2022 Non-metastatic HSPC – XTANDI plus ADT ER/PgR+ Breast Cancer ARCHES Metastatic HSPC – XTANDI plus ADT Hepatocellular Carcinoma Potential
Slide 22: Innovative Late-Stage Pipeline: Talazoparib and Pidilizumab
Innovative Late-Stage Pipeline: Talazoparib and Pidilizumab
Slide 23: Talazoparib: Potential Best-in-Class PARP Inhibitor for Breast Cancer and Beyond
Talazoparib – Potential Best-in-Class PARP Inhibitor for Breast Cancer and Beyond Significantly greater potency in vitro relative to other PARPi’s Unique PARP-trapping ability Differentiated Mechanism of Action Compelling Clinical Data High / differentiated response rate observed in ovarian and brea
Slide 24: PARP Inhibitors Have Demonstrated Striking Effects in Advanced mCRPC
PARP Inhibitors Have Demonstrated Striking Effects in Heavily Pre-treated, Advanced mCRPC Data from Olaparib Study in Advanced Prostate Cancer Patients dosed 50 Evaluable for response 49 Prior lines of treatment n (%) Docetaxel 50 (100%) Cabazitaxel 29 (58%) Abiraterone 48 (96%) Enzalutamide 14 (28%
Slide 25: PARP Trapping Better Correlated to Antitumor Activity
Source: Shen et al. Clin Cancer Res 2013; 19:5003–15. Note: PARP inhibition represents relative concentration for 50% inhibition in PARP1 enzyme assay; antitumor activity represents relative concentration for 50% Capan-1 cell survival reduction in single-agent cytotoxicity assay; and temozolomide po
Slide 26: Superior PARP Trapping May Lead to Improved Clinical Outcomes
Phase 1 Response Data (talazoparib with low-dose chemotherapy) Superior PARP Trapping May Lead to Improved Clinical Outcomes in Broad Patient Populations Phase 1 data from a 40 patient study of talazoparib in combination with low-dose chemotherapy in heavily pre-treated advanced malignancies 4/7 obj
Slide 27: Third-Party Comparison of PARP Data Supports Talazoparib's Best-In-Class Potential
Third-Party Comparison of PARP Data Supports Talazoparib’s Best-In-Class Potential Olaparib Niraparib Talazoparib Phase 2 Breast POC Phase 2 Phase 1/2 Phase 1 Dosing 100mg BID 400mg BID 400mg BID Various 0.9–1.1mg QD 1mg QD Size, n 27 27 62 4 18 14 Prior Regimens, median 3 3 4.6 5 3 Platinum 22% 30%
Slide 28: Adverse Event Profile of Talazoparib vs. Other PARP Inhibitors
Adverse Event Profile of Talazoparib vs. Other PARP Inhibitors Niraparib: >10% pts Rucaparib: >15% pts Source: BioMarin. Wainburg et.al. ASCO 2014 (1mg patients). Kaufman et.al. ASCO 2013 (400mg patients). Sandu et.al. Lancet Oncology 2013 (290-300mg patients). Swisher et.al. SGO 2015 (600mg patient
Slide 29: EMBRACA Is Similar to Competitor Trials, but More Conservatively Designed
Phase 3 EMBRACA Is Similar to Competitor Trials, but More Conservatively Designed Source: Management, company filings and ClinicalTrials.gov.
Slide 30: Strategic and Disciplined Development Approach to Maximizing Talazoparib
Our Strategic and Disciplined Development Approach to Maximizing the Talazoparib Opportunity Tumor Type Development Plan Opportunity for Talazoparib Breast Cancer Complete EMBRACA enrollment by YE Initiate Beyond BRCA registrational trial in 2H 2016 No ongoing registrational trials for other PARPi’s
Slide 31: Talazoparib Potentiates Temozolomide Tumor Kill in SCLC Xenografts
Talazoparib Potentiates Temozolomide Tumor Kill in Small Cell Lung Cancer Xenografts at Submaximal Doses SCLC Represents One of Our First Registrational Trial Opportunities for Talazoparib Vehicle Temozolomide 3mg/kg PO QD x 4 Talazoparib 0.25 mg/kg PO QD x 4 Talazoparib + Temozolomide Medivation; d
Slide 32: Talazoparib's Mechanism of Action May Address Multiple Tumor Types
Talazoparib’s Mechanism of Action May Address Multiple Tumor Types * Potential addressable patient population defined as all lines of treatable metastatic patients in 2016. Dollar figures reflect current PARP inhibitor pricing Sources: MDVN internal analysis; Peshkin et al, Breast Dis. 2010; TCGA, N
Slide 33: Pidilizumab (MDV9300): Antibody With Immune-Mediated Antitumor Effects
Pidilizumab (MDV9300) – Antibody With Immune-Mediated Antitumor Effects Progress has been made in elucidating pidilizumab’s immune-activating mechanism of action Potentially Novel Mechanism of Action Supported by Strong Clinical Evidence to Date Administered to several hundred patients and activity
Slide 34: Sanofi's Substantially Inadequate and Opportunistically-Timed Proposal
Sanofi’s Substantially Inadequate and Opportunistically-Timed Proposal
Slide 35: Sanofi's Opportunistic Proposal Substantially Undervalues Medivation
Sanofi’s Opportunistic Proposal Substantially Undervalues Medivation Sanofi’s proposed price of $52.50 per share substantially undervalues Medivation: Medivation is a unique opportunity as one of the few profitable and sizeable oncology companies Medivation has built XTANDI into a rapidly-growing, m
Slide 36: Sanofi's Unaffected Price Coincided with NASDAQ Biotechnology Index Bottom
Sanofi’s “Unaffected Price” Coincided with NASDAQ Biotechnology Index Bottom Source: FactSet, Company filings Medivation Share Price NBI Indexed Price (as of 01/01/15) 140 130 120 110 100 90 80 70 60 NASDAQ Biotech Index Bottom: February 11, 2016 Sanofi’s implied “unaffected price” of $35.00 “Unaffe
Slide 37: Few Companies Have What Medivation Has: Blockbuster Product plus Late-Stage Pipeline
Few Companies Have What Medivation Has: Blockbuster Product plus Late-Stage Pipeline Overview of Precedent Transactions Source: Company press releases and Company filings ¹ Transaction values as quoted by the acquirors’ press release on date of transaction announcement ² Includes upfront payment of
Slide 38: Recent Third-Party Transactions Validate the Value of Medivation's Key Assets
“There are several lines of evidence that PARP inhibition may be effective in prostate cancer and up to 50% of men with prostate cancer may be eligible for niraparib… We view the Janssen deal as highly validating of niraparib and providing a pathway to a substantial commercial opportunity” ̶ Wells F
Slide 39: Medivation Has Full Confidence in Achieving its Goals
Medivation Has Full Confidence in Achieving its Goals Key Variables Creating Gap Between Our 2020 Revenue Targets and Consensus Management Revenue Targets vs. Consensus Estimates (1) (2) ~28% CAGR Capitalizing on a substantial, near-term commercial opportunity in urology Successfully moving even ear
Slide 40: Conclusion
ke MEDIVATION® Conclusion
Slide 41: We are Executing on Our Strategic Plan and Delivering Meaningful Value
We are Executing on Our Strategic Plan and Delivering Meaningful Value to Patients and Shareholders Developed the World’s Leading Prostate Cancer Therapy $2.2 Billion Annualized Run Rate in Worldwide XTANDI Net Sales Wholly-Owned, Late-Stage Assets with Blockbuster Potential XTANDI Development: One